Back to research
    Deep Dive

    CBL-514: What the Published Research Shows

    November 20268 min readBy the Peptx research team

    CBL-514 is an investigational small molecule, not a peptide, from Caliway Biopharmaceuticals. What the published phase 2 papers show, how it is said to work, where phase 3 stands as of November 2026, and what is still unknown.

    Quick Answer

    CBL-514 is an investigational small molecule, not a peptide, developed by Caliway Biopharmaceuticals. Published phase 2 trials report that it reduced fat under the skin of the abdomen compared with placebo, and the papers attribute this to programmed death (apoptosis) of fat cells. As of November 2026 it is in phase 3, is not approved anywhere, and most of what is known comes from short, company-funded studies.

    Key facts

    • Compound type: small molecule (described as such in the trial papers); not a peptide or protein.
    • Structure, formula, CAS number: not given in the published papers; we found no PubChem entry under this name (checked November 2026).
    • Developer: Caliway Biopharmaceuticals, Taiwan.
    • Proposed mechanism: induction of fat cell (adipocyte) apoptosis; the supporting laboratory data are cited as unpublished company reports.
    • Published human studies: three abdominal fat trials (2022, 2025, 2026) and one small Dercum's disease study (2025).
    • Highest stage (November 2026): phase 3; SUPREME-01 and SUPREME-02 are enrolling and have not read out.
    • Approval status (November 2026): not approved in any country.

    CBL-514 has been widely discussed online during 2026, often alongside research peptides, although it is a different kind of compound. This article sets out what the published papers and trial registry entries actually say, and where the gaps are.

    Is CBL-514 a peptide?

    No. Peptides are short chains of amino acids. The trial papers call CBL-514 a small-molecule lipolysis agent (Gold et al., 2025; Lorenc et al., 2026), and the developer uses the same term. Beyond that, very little chemistry is public. None of the published papers gives a structure, a molecular formula or a CAS number, so the identity of the molecule cannot be checked against an independent reference. By contrast, AOD-9604 (a peptide fragment) and 5-Amino-1MQ (a small molecule) have published structures.

    How is CBL-514 said to work?

    The papers describe one core idea: CBL-514 causes fat cells in the treated area to undergo apoptosis, the orderly, programmed form of cell death, so the number of fat cells falls. The most detailed account is in the discussion of the first phase 2 paper (Goodman et al., 2022). It reports the following, each from the developer's own studies:

    • Cell culture (mature 3T3-L1 mouse fat cells): higher caspase-3 activation, a higher Bax to Bcl-2 ratio and more Annexin V staining than in untreated cells or cells treated with deoxycholic acid. These are standard laboratory markers of apoptosis.
    • Rodents: less fat under the skin in the treated area, with a higher Bax to Bcl-2 ratio in that fat than in controls.
    • Rodent and dog toxicology: no tissue death (necrosis) seen under the microscope around the treated site.
    • Target: the paper states that CBL-514 inhibits DYRK1B, a kinase involved in cell survival.

    Every one of these points is cited in the paper to "unpublished confidential reports" from the company. As of November 2026 we could find no peer-reviewed paper presenting the underlying laboratory data, and no independent group has reported repeating it. The DYRK1B statement does appear in a journal article, but only as a summary of company data that readers cannot inspect.

    What have the published human trials shown?

    Three trials in abdominal fat have been published, all in Aesthetic Surgery Journal and all funded by the developer. Each measured subcutaneous fat (the layer under the skin) by imaging.

    • Phase 2a (Goodman et al., 2022; NCT04698642): an open-label study at one site in Australia. 43 people were enrolled and allocated to one of three strength levels, with no placebo group. Fat volume and thickness by ultrasound fell from baseline at the two higher levels. 15 participants withdrew, 8 of them because of adverse events.
    • Phase 2 (Gold et al., 2025; NCT04897412): a single-blind, placebo-controlled trial at five centres in the United States and Australia. 76 people were randomised two to one (50 to CBL-514, 26 to placebo) and had up to four treatments. The main measure was the share of people losing at least 150 mL of abdominal subcutaneous fat by ultrasound. Eight weeks after the last treatment that was 16 of 23 (69.6%) with CBL-514 and 0 of 16 with placebo.
    • Phase 2b (Lorenc et al., 2026; NCT05736107): a single-blind, placebo-controlled trial in 108 adults, randomised one to one, with up to four treatments. The main measure was a one-grade improvement on a clinician-rated abdominal fat scale: 23 of 30 (76.7%) with CBL-514 against 7 of 37 (18.9%) with placebo. MRI showed a mean fall in abdominal fat volume of about 20% from baseline in the CBL-514 group, which was larger than with placebo.

    Three cautions apply. "Single-blind" means participants did not know which treatment they had, but investigators did. The analysed groups were much smaller than the randomised groups: in the 2025 trial 49.3% of participants did not complete, which the authors attribute to strict rules on weight stability and visit timing. And follow-up ended 8 to 12 weeks after treatment, so the papers do not show how long any change lasts.

    What adverse events were reported?

    Reactions at the treated area were close to universal. In the 2025 trial, 98% of the CBL-514 group and all of the placebo group reported at least one treatment-related event. Redness, pain, itching, swelling and warmth were each reported by more than 80% of the CBL-514 group (Gold et al., 2025). Most events were mild or moderate. Nine of 49 participants (18.4%) reported severe pain at the treated site, against none on placebo, and two stopped because of a treatment-related event. One participant had a moderate rise in blood lipids judged probably related. The authors reported no skin necrosis, ulceration or nerve injury.

    Which other studies are registered?

    • Dercum's disease: a rare condition with painful fatty lumps (lipomas). A phase 2a study of 12 adults with no comparator group reported median lipoma volume reductions of about 45% to 59% by ultrasound and lower pain scores (Herbst et al., 2025; NCT05387733). A placebo-controlled phase 2 study in 19 people (NCT06303570) is listed as completed; the company has reported that it met its pain endpoint, but it is not yet published.
    • Cellulite (edematous fibrosclerotic panniculopathy, EFP): a two-stage phase 2 study (NCT05632926 and NCT05836779) is listed as completed. We found no peer-reviewed report of its results.
    • Pharmacokinetics: a study in 10 healthy volunteers (NCT05234736) and a phase 1 safety study in 40 (NCT04699669) are listed as completed. We found no journal publication of either.

    Where does phase 3 stand?

    SUPREME-01 (CBL-0301, NCT07140939) is a randomised, double-blind, placebo-controlled phase 3 trial planned for about 320 participants in the United States and Canada. The company announced that the first participant was treated on 23 September 2026. The main measure is a two-grade improvement on both a patient-rated and a clinician-rated abdominal fat scale, with MRI as a key secondary measure. The registry lists an estimated primary completion date of July 2027, so results are not expected before 2027. A second trial of the same size, SUPREME-02 (CBL-0302, NCT07526974), began enrolling in October 2026, and a long-term follow-up study (NCT07733947) is registered but not yet recruiting.

    The company has also reported preclinical work combining CBL-514 with weight-management compounds. According to its press releases, a preclinical study scheduled for presentation at ObesityWeek on 15 November 2026 found additive weight loss when CBL-514 was combined with semaglutide (a GLP-1 receptor agonist) or eloralintide (an amylin receptor agonist), and less weight regain after treatment stopped. These are company-reported preclinical findings that have not been peer reviewed, and the releases give no methods. Our guide to GLP-1 peptides covers that class.

    How does it differ from deoxycholic acid?

    CBL-514 is not approved by any regulator as of November 2026. The established medicine of this broad kind is deoxycholic acid (ATX-101), which the US FDA approved in 2015 for fat under the chin only (Dunican and Patel, 2016). Deoxycholic acid is a bile acid that acts as a detergent. Laboratory work showed that it bursts cell membranes without regard to cell type (Rotunda et al., 2004), and that its relative selectivity for fat in living tissue probably comes from fat being low in the proteins that neutralise it (Thuangtong et al., 2010). That is cell lysis, a destructive form of cell death that provokes inflammation, which is quite different from apoptosis, where a cell dismantles itself in a controlled way. Whether that difference holds for CBL-514 in human tissue has been asserted in the trial papers but not shown in published tissue studies.

    What is not known?

    • The molecule itself. No structure or formula is in the published papers. The developer stated on 30 October 2026 that CBL-514 is not commercially available and that no third party is authorised to supply it, so material offered online under this name has no published identity standard to be checked against.
    • Independent replication. Every published trial was funded by the developer, with company employees among the authors, and the mechanism data are unpublished.
    • Long-term outcomes. Published follow-up is 12 weeks at most. Durability and long-term safety are untested in print.
    • Larger and more varied populations. The published trials total about 240 people, mostly white women, with heavy drop-out.
    • Phase 3. Neither SUPREME trial has reported. Positive phase 2 results do not always survive larger, double-blind testing.

    Bottom line

    CBL-514 is a real development candidate with three published phase 2 trials and two phase 3 trials under way. It is also a small molecule of undisclosed structure whose mechanism rests on unpublished company data, tested so far in short, single-blind, company-funded studies. The phase 3 results are the evidence that will settle most of the open questions. More articles are in our research library.

    References

    1. Goodman GJ, et al. (2022). Efficacy of a novel injection lipolysis to induce targeted adipocyte apoptosis: a randomized, phase IIa study of CBL-514 injection on abdominal subcutaneous fat reduction. Aesthetic Surgery Journal. PubMed 35709509
    2. Gold M, et al. (2025). Efficacy and safety of CBL-514 injection in reducing abdominal subcutaneous fat: a randomized, single-blind, placebo-controlled phase II study. Aesthetic Surgery Journal. PubMed 40037659
    3. Lorenc ZP, et al. (2026). Randomized phase 2b trial of CBL-514 injection for abdominal subcutaneous fat reduction with clinician- and patient-reported outcomes and MRI assessment. Aesthetic Surgery Journal. PubMed 42159040
    4. Herbst KL, et al. (2025). Efficacy and safety of CBL-514 for Dercum disease lipomas: a randomized phase 2a study. JAAD International. PubMed 41623934
    5. Rotunda AM, et al. (2004). Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution. Dermatologic Surgery. PubMed 15209790
    6. Thuangtong R, et al. (2010). Tissue-selective effects of injected deoxycholate. Dermatologic Surgery. PubMed 20482723
    7. Dunican KC, Patel DK (2016). Deoxycholic acid (ATX-101) for reduction of submental fat. Annals of Pharmacotherapy. PubMed 27340142
    8. ClinicalTrials.gov. A study to evaluate the efficacy and safety of CBL-514 injection for reducing subcutaneous fat (SUPREME-01), NCT07140939. clinicaltrials.gov
    9. Caliway Biopharmaceuticals (23 September 2026). Caliway announces first patient dosed in global phase 3 SUPREME-01 trial of CBL-514; new preclinical data accepted for presentation at ObesityWeek 2026. caliwaybiopharma.com
    10. Caliway Biopharmaceuticals (29 October 2026). Caliway advances dual global phase 3 program as SUPREME-02 enrollment begins. caliwaybiopharma.com
    11. Caliway Biopharmaceuticals (30 October 2026). Caliway Biopharmaceuticals clarifies unauthorized online claims regarding CBL-514. caliwaybiopharma.com

    Frequently asked questions

    What is CBL-514?

    CBL-514 is an investigational small-molecule compound developed by Caliway Biopharmaceuticals of Taiwan. In published human trials it has been studied for reducing fat under the skin of the abdomen, and in small studies for Dercum's disease lipomas and cellulite. As of November 2026 it is in phase 3 trials and is not approved in any country.

    Is CBL-514 a peptide?

    No. The published trial papers and the developer describe CBL-514 as a small molecule, not a peptide or protein. Its chemical structure, formula and CAS number are not given in the published papers, so the exact molecule cannot be confirmed from public sources.

    How does CBL-514 work?

    The published papers say it triggers apoptosis, a form of programmed cell death, in fat cells (adipocytes). The detail behind that statement, including raised caspase-3 activity and a higher Bax to Bcl-2 ratio in cultured 3T3-L1 mouse fat cells, comes from company studies that the papers cite as unpublished reports. It has not been confirmed by an independent laboratory.

    Is CBL-514 approved?

    No. As of November 2026 CBL-514 is not approved by any medicines regulator. The developer stated on 30 October 2026 that it remains an investigational candidate and is not commercially available in any market. Two phase 3 trials, SUPREME-01 and SUPREME-02, are under way and have not reported results.

    What did the phase 2 trials of CBL-514 find?

    Three trials in abdominal fat have been published in Aesthetic Surgery Journal (2022, 2025 and 2026). The two placebo-controlled trials reported larger reductions in abdominal fat under the skin than placebo, measured by ultrasound or MRI. Both were single-blind, company-funded and short, and many participants were not included in the main analyses.

    What side effects were reported in CBL-514 trials?

    Mainly local reactions at the treated area: redness, pain, itching, swelling, warmth, bruising, discolouration and firmness. In the 2025 phase 2 paper nearly every participant in both groups reported at least one, most were mild or moderate, and 9 of 49 people who received CBL-514 reported severe pain at the treated site.

    Related research

    What net peptide content meansBrowse the research library

    Browse the Peptx catalogue

    Independently tested compounds, typically 99%+ purity (HPLC), factory-direct pricing. UK stock orders placed by 3pm are posted the same day.

    Sold strictly for laboratory research. Not for human consumption.